Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8447035 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL21219839 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL29398297 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL15788340 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL13640175 | 0.96 | MDM4 (0.49) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL30206885 | 0.94 | MDM4 (0.47) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL27008576 | 0.93 | MDM4 (0.49) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL27129147 | 0.93 | MDM4 (0.49) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL10310984 | 0.93 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL29746914 | 0.91 | MDM4 (0.50) | MDM4TP53MDM2CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4172142-A1 | BRANCHED LIPID COMPOUNDS | Ena Respiratory Pty Ltd (AU) | 2023-05-03 | — | — | EP | disclosed |
| EP-4157255-A1 | TREATMENT OF CORONAVIRUS | Ena Respiratory Pty Ltd (AU) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023028661-A1 | FORMULATION | Ena Respiratory Pty Ltd (AU) | 2023-03-09 | — | — | WO | disclosed |
| EP-4025203-A1 | CANCER TREATMENT | Axelia Oncology Pty Ltd (AU) | 2022-07-13 | — | — | EP | disclosed |
| EP-4025204-A1 | CANCER IMMUNOTHERAPY | Axelia Oncology Pty Ltd (AU) | 2022-07-13 | — | — | EP | disclosed |
| EP-3990428-A1 | NOVEL MOLECULES | Axelia Oncology Pty Ltd (AU) | 2022-05-04 | — | — | EP | disclosed |